We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-0.37%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.75B
AUM Growth
-$41.8M
Cap. Flow
+$154M
Cap. Flow %
2.69%
Top 10 Hldgs %
69.08%
Holding
53
New
7
Increased
13
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$253M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$146M
3
GLUE icon
Monte Rosa Therapeutics
GLUE
+$67.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$52.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$28.6M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$128M
2
TVTX icon
Travere Therapeutics
TVTX
+$31.2M
3
RLMD icon
Relmada Therapeutics
RLMD
+$20.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$17.9M
5
RLAY icon
Relay Therapeutics
RLAY
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$843M 14.66%
9,000,000
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$808M 14.05%
5,000,000
+325,000
+7% +$52.2M
UTHR icon
3
United Therapeutics
UTHR
$25.9B
$538M 9.36%
3,000,000
– –
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$376M 6.55%
3,000,000
– –
ARGX icon
5
argenx
ARGX
$54.9B
$285M 4.96%
946,500
+21,000
+2% +$5.97M
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
$278M 4.83%
4,075,000
+25,000
+0.6% +$1.63M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.6B
$250M 4.35%
+1,900,000
New +$253M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.03B
$237M 4.12%
9,100,000
+1,100,000
+14% +$28.6M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.64B
$187M 3.25%
2,400,000
+250,000
+12% +$19M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$38.1B
$170M 2.95%
+1,000,000
New +$146M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$124B
$159M 2.77%
790,000
-610,000
-44% -$128M
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$12.4B
$139M 2.41%
1,425,000
– –
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.9B
$138M 2.4%
1,650,000
– –
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$120M 2.09%
12,450,000
+200,000
+2% +$1.95M
CNST
15
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$108M 1.89%
3,210,000
+260,000
+9% +$6.63M
MRSN
16
DELISTED
Mersana Therapeutics
MRSN
$92.3M 1.61%
272,000
– –
KURA icon
17
Kura Oncology
KURA
$785M
$86.3M 1.5%
4,140,000
+140,000
+4% +$3.48M
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.16B
$68M 1.18%
3,650,000
– –
APLS
19
DELISTED
Apellis Pharmaceuticals
APLS
$63.5M 1.11%
1,005,230
+5,230
+0.5% +$270K
PMVP icon
20
PMV Pharmaceuticals
PMVP
$57.6M
$62.3M 1.08%
1,825,000
-535,267
-23% -$17.9M
GLUE icon
21
Monte Rosa Therapeutics
GLUE
$1.82B
$62.2M 1.08%
+3,311,434
New +$67.4M
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$4.45B
$59.6M 1.04%
2,441,658
-58,342
-2% -$1.32M
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$58M 1.01%
3,235,000
– –
TRIL
24
DELISTED
Trillium Therapeutics Inc.
TRIL
$55.3M 0.96%
5,700,000
– –
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.68B
$51.5M 0.9%
3,000,000
+500,000
+20% +$9.16M
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Avoro Capital Advisors held 53 positions worth $5.75B, down 0.72% from $5.79B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors's Q2 2021 filing shows 7 new, 13 increased, 8 reduced and 7 closed positions. Its largest new stake was Ascendis Pharma A/S: 1,900,000 shares worth $250M. The largest sale was Vertex Pharmaceuticals, an estimated $128M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

  • Avoro Capital Advisors's largest Q2 2021 buy was Ascendis Pharma A/S: 1,900,000 shares worth $250M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $52.2M increase.
  • Avoro Capital Advisors's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $128M.
  • Avoro Capital Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $31.2M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.75B portfolio in Q2 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 7 in Q2 2021.
  • Avoro Capital Advisors's portfolio value fell 0.72% quarter-over-quarter to $5.75B.

Based on Avoro Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.